当前位置：
X-MOL 学术
›
Adv. Healthcare Mater.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Antiaggregation of NIR-II Probe Regulated by Amphiphilic Polypeptide with High Contrast Brightness for Phototheranostics and Vascular Microscopic Imaging under 1064 nm Irradiation
Advanced Healthcare Materials ( IF 10.0 ) Pub Date : 2023-04-29 , DOI: 10.1002/adhm.202300541 Changchang Teng 1, 2 , Huiping Dang 2 , Yixuan Xu 2 , Dalong Yin 1 , Lifeng Yan 1, 2
Advanced Healthcare Materials ( IF 10.0 ) Pub Date : 2023-04-29 , DOI: 10.1002/adhm.202300541 Changchang Teng 1, 2 , Huiping Dang 2 , Yixuan Xu 2 , Dalong Yin 1 , Lifeng Yan 1, 2
Affiliation
|
Thanks to deep penetration and high resolution, the second near-infrared window (NIR-II, 1000–1700 nm) fluorescence (FL) imaging is expected to gain favor in clinical applications, including macroscopic imaging for cancer diagnosis and microangiography for vascular-related disease diagnosis. Nevertheless, most NIR-II fluorescent probes, especially cyanine, are highly susceptible to self-quenching in the aggregated state, which severely limits their application in bioimaging. Here, the Br-modified cyanine dye F4-Br and the amphiphilic polypeptide poly(oligo[ethylene glycol]methacrylate)-b-poly(benzyl-L-aspartic acid) (POEGMA-PBLA) are synthesized. By modulating the self-assembly of F4-Br and POEGMA-PBLA to effectively inhibit the H-aggregation of F4-Br in aqueous solutions, nanoprobe F4-Br@P17 with outstanding antiquenching capability is developed. This prominent feature allows it to perform vascular microscopic imaging with high spatiotemporal resolution and assess hemodynamic characteristics. F4-Br@P17 nanoparticles (NPs) with good stability and satisfactory biocompatibility also enable high contrast brightness for NIR-II FL imaging of tumors. Given the efficient enrichment at tumor sites and the promising photothermal conversion efficiency (43.5%), F4-Br@P17 NPs successfully conduct photothermal therapy and exhibit superior antitumor efficiency under 1064 nm laser irradiation. These remarkable performances reveal the tremendous possibility of F4-Br@P17 NPs for in vivo microscopic imaging and FL imaging-guided photothermal therapy in the NIR-II region.
中文翻译：
高对比度两亲性多肽调控 NIR-II 探针的抗聚集，用于 1064 nm 照射下的光治疗和血管显微成像
凭借深度穿透和高分辨率，第二近红外窗口（NIR-II，1000-1700 nm）荧光（FL）成像有望在临床应用中获得青睐，包括用于癌症诊断的宏观成像和用于血管相关的微血管造影疾病诊断。然而，大多数NIR-II荧光探针，尤其是花青，在聚集状态下极易发生自猝灭，这严重限制了它们在生物成像中的应用。这里，合成了Br修饰的花青染料F 4 -Br和两亲性多肽聚(低聚[乙二醇]甲基丙烯酸酯)-b-聚(苄基-L-天冬氨酸)(POEGMA-PBLA)。通过调节F 4 -Br和POEGMA-PBLA的自组装来有效抑制水溶液中F 4 -Br的H聚集，开发出具有出色的古董淬火能力的纳米探针F 4 -Br@P 17 。这一突出的功能使其能够以高时空分辨率进行血管显微成像并评估血流动力学特征。F 4 -Br@P 17纳米粒子（NPs）具有良好的稳定性和令人满意的生物相容性，也可为肿瘤的NIR-II FL成像提供高对比度亮度。鉴于在肿瘤部位的有效富集和令人鼓舞的光热转换效率（43.5％），F 4 -Br@P 17 NPs成功地进行光热治疗，并在1064 nm激光照射下表现出优异的抗肿瘤效率。这些卓越的性能揭示了 F 4 -Br@P 17 NP 在 NIR-II 区域体内显微成像和 FL 成像引导光热治疗中的巨大可能性。
更新日期：2023-04-29
中文翻译：
高对比度两亲性多肽调控 NIR-II 探针的抗聚集，用于 1064 nm 照射下的光治疗和血管显微成像
凭借深度穿透和高分辨率，第二近红外窗口（NIR-II，1000-1700 nm）荧光（FL）成像有望在临床应用中获得青睐，包括用于癌症诊断的宏观成像和用于血管相关的微血管造影疾病诊断。然而，大多数NIR-II荧光探针，尤其是花青，在聚集状态下极易发生自猝灭，这严重限制了它们在生物成像中的应用。这里，合成了Br修饰的花青染料F 4 -Br和两亲性多肽聚(低聚[乙二醇]甲基丙烯酸酯)-b-聚(苄基-L-天冬氨酸)(POEGMA-PBLA)。通过调节F 4 -Br和POEGMA-PBLA的自组装来有效抑制水溶液中F 4 -Br的H聚集，开发出具有出色的古董淬火能力的纳米探针F 4 -Br@P 17 。这一突出的功能使其能够以高时空分辨率进行血管显微成像并评估血流动力学特征。F 4 -Br@P 17纳米粒子（NPs）具有良好的稳定性和令人满意的生物相容性，也可为肿瘤的NIR-II FL成像提供高对比度亮度。鉴于在肿瘤部位的有效富集和令人鼓舞的光热转换效率（43.5％），F 4 -Br@P 17 NPs成功地进行光热治疗，并在1064 nm激光照射下表现出优异的抗肿瘤效率。这些卓越的性能揭示了 F 4 -Br@P 17 NP 在 NIR-II 区域体内显微成像和 FL 成像引导光热治疗中的巨大可能性。
京公网安备 11010802027423号